Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro

Mathieu Roumiguié; Peter C Black

doi:10.1016/j.euf.2021.07.018

Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro

Eur Urol Focus. 2022 Jul;8(4):1117-1120. doi: 10.1016/j.euf.2021.07.018. Epub 2021 Sep 27.

Authors

Mathieu Roumiguié¹, Peter C Black²

Affiliations

¹ Department of Urology, CHU Institut Universitaire du Cancer de Toulouse, Toulouse, France; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. Electronic address: [email protected].
² Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.

PMID: 34593355
DOI: 10.1016/j.euf.2021.07.018

Abstract

Docetaxel and gemcitabine have different mechanisms of action, are well tolerated as monotherapies, and are affordable. This combination represents a good option for the second-line, bladder-preserving standard of care for non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.

MeSH terms

Administration, Intravesical
BCG Vaccine* / therapeutic use
Deoxycytidine / analogs & derivatives
Docetaxel / therapeutic use
Gemcitabine
Humans
Neoplasm Invasiveness
Urinary Bladder Neoplasms* / drug therapy

Substances

BCG Vaccine
Deoxycytidine
Docetaxel
Gemcitabine